| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CALML5 |
| Uniprot No | Q9NZT1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-146aa |
| 氨基酸序列 | AGELTPEEEAQYKKAFSAVDTDGNGTINAQELGAALKATGKNLSEAQLRKLISEVDSDGDGEISFQEFLTAAKKARAGLEDLQVAFRAFDQDGDGHITVDELRRAMAGLGQPLPQEELDAMIREADVDQDGRVNYEEFARMLAQE |
| 预测分子量 | 31.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CALML5重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**: *"Characterization of CALML5 as a novel calcium-binding protein in epidermal differentiation"*
**作者**: Smith A, et al.
**摘要**: 本研究通过在大肠杆菌中表达重组CALML5蛋白，发现其具有钙离子依赖性结合特性，并证明其在表皮角质形成细胞分化中通过调节钙信号通路促进终末分化。
2. **文献名称**: *"Recombinant CALML5 inhibits cell proliferation in cutaneous squamous cell carcinoma"*
**作者**: Lee JH, et al.
**摘要**: 利用哺乳动物细胞系统表达纯化的重组CALML5蛋白，发现其能通过结合细胞周期蛋白抑制皮肤鳞状细胞癌的增殖，提示其作为潜在肿瘤抑制因子的作用。
3. **文献名称**: *"Structural insights into CALML5-calcium interaction by recombinant protein crystallography"*
**作者**: Zhang R, et al.
**摘要**: 通过昆虫细胞表达系统获得高纯度CALML5重组蛋白，解析其晶体结构，揭示了其与钙离子结合的独特构象，为理解其分子功能提供了结构基础。
注：以上文献信息为基于领域知识的示例，若需真实文献，建议通过PubMed或Web of Science以“CALML5 recombinant”为关键词检索。
CALML5 (Calmodulin-like protein 5), also known as CLP, is a small calcium-binding protein belonging to the EF-hand protein superfamily. It shares structural homology with calmodulin but exhibits distinct tissue-specific expression patterns, primarily localized in epithelial tissues, particularly the skin, hair follicles, and stratified squamous epithelia. First identified in the early 2000s, CALML5 is implicated in regulating cellular processes such as differentiation, proliferation, and apoptosis through calcium-dependent signaling pathways. Its unique N-terminal extension and differential calcium-binding affinity distinguish it from other calmodulin family members, suggesting specialized roles in epithelial homeostasis.
Recombinant CALML5 is produced via heterologous expression systems (e.g., E. coli or mammalian cells) for functional studies. The protein’s structure includes four EF-hand motifs, though only two bind calcium with high affinity. This feature enables it to act as a calcium sensor with nuanced regulatory capabilities in keratinocyte differentiation and epidermal barrier formation. Dysregulation of CALML5 has been linked to skin disorders like psoriasis and squamous cell carcinoma, driving interest in its therapeutic or diagnostic potential.
Recent studies focus on its interactions with cytoskeletal proteins (e.g., annexins) and transcription factors, revealing mechanisms in cell adhesion and gene expression control. Challenges in recombinant production include optimizing solubility and post-translational modifications to mimic native isoforms. As a research tool, recombinant CALML5 aids in deciphering calcium signaling networks in epithelial biology, with emerging applications in dermatological drug development and cancer biomarker discovery. Its tissue specificity and regulatory versatility make it a compelling target for both basic research and translational medicine.
×
